在細(xì)胞治療領(lǐng)域，納米磁珠的突破從未停歇。ACROBiosystems百普賽斯首款實(shí)現(xiàn)“全自主技術(shù)閉環(huán)”的全新一代Cellectra™系列CD4、CD8 T細(xì)胞納米分選磁珠正式問(wèn)世！我們以技術(shù)創(chuàng)新為刃，直面行業(yè)在材料不對(duì)標(biāo)、穩(wěn)定性不足、批間差異明顯、臨床轉(zhuǎn)化困難等核心痛點(diǎn)，經(jīng)過(guò)多維度重復(fù)驗(yàn)證，以扎實(shí)數(shù)據(jù)與嚴(yán)苛標(biāo)準(zhǔn)為支撐，以臨床級(jí)安全為核心，依托全自主技術(shù)閉環(huán)與高標(biāo)準(zhǔn)合規(guī)體系，為細(xì)胞分選提供安全、穩(wěn)定、高效的一體化解決方案。
為什么選擇Cellectra™系列產(chǎn)品？七大硬核實(shí)力給出答案：
-
性能領(lǐng)先：低非特異吸附、微量高效，核心指標(biāo)達(dá)國(guó)際領(lǐng)先水平；
-
原料真實(shí)可溯：醫(yī)療級(jí)葡聚糖，安全可靠，打造純凈基底；
-
技術(shù)閉環(huán)：磁珠+抗體雙平臺(tái)，100%自主可控，全鏈條貫通；
-
超長(zhǎng)效期：效期2年+，反復(fù)凍融不失效，降低管理成本；
-
產(chǎn)能無(wú)憂：單批次十萬(wàn)支級(jí)，全鏈垂直整合，杜絕卡脖子；
-
批間一致：全流程嚴(yán)控，終結(jié)批次波動(dòng)；
-
合規(guī)貫通：RG&GMP全場(chǎng)景覆蓋，無(wú)縫銜接科研與臨床。
ACROBiosystems百普賽斯現(xiàn)重磅推出Cellectra™系列CD4和CD8 T細(xì)胞納米分選磁珠：
-
磁珠材質(zhì)鑒定
Cellectra™ 系列納米磁珠采用醫(yī)療級(jí)葡聚糖包裹的氧化鐵納米顆粒為原料，具備生物可降解性。磁珠能被抗葡聚糖單克隆抗體（anti-dextran mAb）識(shí)別。實(shí)驗(yàn)結(jié)果表明，ACROBiosystems百普賽斯與Company M的磁珠均呈抗葡聚糖抗體陽(yáng)性，而另外兩家商業(yè)化磁珠為陰性。由此證明，ACRO納米磁珠生產(chǎn)關(guān)鍵原料信息真實(shí)可溯、安全特征清晰明確，能夠?yàn)榭蛻羲幬锏纳a(chǎn)與申報(bào)工作提供穩(wěn)定可靠的材料保障。
Human PBMCs (4×107 total cells) were co-isolated using CD4 and CD8 Microbeads (recommended dosage) from Acro and other company products (Company M, Company T, Company G). Post-co-isolation cells from each manufacturer were stained with FITC anti-dextran antibody, PE anti-human CD3 antibody, and 7-AAD, then analyzed by flow cytometry. Notably, no dextran signal from bead-attached cells was detected for Company T or Company G.
-
分選性能對(duì)標(biāo)競(jìng)品（單磁珠分選/雙磁珠聯(lián)合分選）
取等量人外周血單個(gè)核細(xì)胞（PBMC），分別采用ACROBiosystems百普賽斯Cellectra™分選磁珠及其他多款商業(yè)化磁珠，在相同條件下進(jìn)行單一細(xì)胞分選或CD4&CD8細(xì)胞聯(lián)合分選。結(jié)果顯示，我們的Cellectra™磁珠在分選后獲得的細(xì)胞純度上，達(dá)到其他商業(yè)化磁珠同等水平或表現(xiàn)出更優(yōu)的性能。
CellectraTM Human CD4 NanoSort Microbeads
The CD4+ cells were isolated from 1×107human PBMCs using 20μL CellectraTM Human CD4 NanoSort Microbeads, Research grade (Cat. No. MBS-S004) , or other company products (Company M, Company T). The isolated cells and non-isolated cells were respectively stained using FITC anti-human CD4 antibody and 7-AAD, and then analyzed by Flow Cytometry.
CellectraTM Human CD8 NanoSort Microbeads
The CD8+ cells were isolated from 1×107 human PBMCs using 20μL CellectraTM Human CD8 NanoSort Microbeads, Research grade (Cat. No. MBS-S005), or other company products (Company M, Company T). The isolated cells and non-isolated cells were respectively stained using PE anti-human CD8 antibody and 7-AAD, and then analyzed by Flow Cytometry.
CD4 NanoSort Microbeads & CD8 NanoSort Microbeads
聯(lián)合分選
Human PBMCs (per 107 cells) were isolated 20 μL CD4 NanoSort Microbeads (Cat. No. MBS-S004) and 20 μL CD8 NanoSort Microbeads (Cat. No. MBS-S005), in parallel with other company products (Company M, Company T). Both the isolated cells and non-isolated cells were stained with FITC anti-human CD4 antibody and PE anti-human CD8 antibody (top) and FITC anti-human CD3 antibody (bottom) as well as 7-AAD, and subsequently analyzed using Flow Cytometry.
-
優(yōu)異的細(xì)胞分選性能
Isolation efficacy was validated using samples containing 1×10? human PBMCs processed with the recommended dosage of Cellectra™ Human CD4 NanoSort Microbeads (Fig. A) or Cellectra™ Human CD8 NanoSort Microbeads (Fig. B), in parallel with other company products (Company M, Company T). Comparative analysis demonstrated that Acro NanoSort Microbeads achieved excellent high purity and recovery rates to other company products. Furthermore, high post-isolation cell viability was preserved, confirming suitability for sensitive downstream applications.
-
全方位穩(wěn)定性驗(yàn)證
多供體兼容性、多批次一致性驗(yàn)證
Minor inter-donor variability was observed in PBMC separation, with high purity and cell recovery consistently maintained (Fig. A). Three batches of CD4 or CD8 NanoSort Microbeads achieved consistent high purity and recovery, confirming robust batch-to-batch consistency and manufacturing reproducibility (Fig. B).
凍融和加速穩(wěn)定性驗(yàn)證
Freeze-thaw stability was verified by subjecting the microbeads to 2–3 cycles prior to separation testing (Fig. A). Comparative analysis against the standard batch confirmed that purity and cell recovery were maintained at baseline specifications, demonstrating robust stability. To ensure prolonged shelf life, storage at -20°C or below is recommended upon receipt (however, repeated freeze-thaw cycles are not advised for routine operational use).
Accelerated aging studies were conducted at 37°C to evaluate long-term stability profiles (Fig. B). Following 7 and 14-day incubation periods, the microbeads sustained high purity and cell recovery performance during PBMC separation. These data substantiate product stability and validate the established shelf-life specifications.
CD4、CD8納米分選磁珠現(xiàn)開(kāi)啟試用裝申請(qǐng)活動(dòng)，掃碼立即參與~
ACROBiosystems
inquiry@acrobiosystems.com
15117918562
（備注：姓名+公司）